The Reply

We agree with Dr. Siegel's comments on our recent article1 that plausible pathophysiologic mechanisms and observational data supporting a benefit for aspirin in Coronavirus Disease 2019 (COVID-19) exist. However, we would not recommend the generalized adoption and use of aspirin for the primary prevention of atherosclerotic cardiovascular disease events in the setting of the COVID-19 pandemic without a well-designed, placebo-controlled, randomized trial showing benefit. Throughout this pandemic, promising therapies have been used widely in patients with and without COVID-19 on the basis of pathophysiologic mechanisms and observational data, including hydroxychloroquine, azithromycin, and tocilizumab.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Letter Source Type: research